Pediatric Respirology and Critical Care Medicine

www.appuls.org

www.hkspra.org

www.pedipulm.org.tw
TOLEDO | SPAIN | JUNE 21-24, 2018
www.cipp-meeting.org

DEADLINES

• Abstract submission: December 15th, 2017
• Notification for acceptance: February 5th, 2018
• Early bird registration: March 5th, 2018

SCIENTIFIC PROGRAM

• Post-graduate courses: Long Term Non Invasive Ventilation, Radiology & Bronchoscopy
• Workshops
• Keynote lectures
• Topic sessions
• Young Investigator’s oral communications
• Interactive poster session

CONTACT INFO
CIPP XVII Secretariat:
18 rue Massena
06000 Nice - FRANCE
Tel. + 33 (0) 4 97 03 85 97
cipp@cipp-meeting.com
Pediatric Respirology and Critical Care Medicine

Official Journal of Asian Paediatric Pulmonology Society, Hong Kong Society of Paediatric Respirology and Allergy, and Taiwan Society of Pediatric Pulmonology and Critical Care Medicine

Editorial Board

Editor-in-Chief
Prof. Gary Wing-kin Wong, Hong Kong

Deputy Editors
Dr. Daniel Kwok-keung Ng, Hong Kong
Dr. Kin-sun Wong, Taiwan

Associate Editors
Dr. Anne Goh, Singapore
Prof. Aroonwan Preuthiphan, Thailand
Prof. Varinder Singh, India
Dr. Rina Triasih, Indonesia

Editorial Board Members
Prof. ARM Luthful Kabir, Bangladesh
Prof. Sushil Kabra, India
Dr. Jin-tack Kim, Korea
Dr. Hussein Al Kindy, Oman
Dr. Carrie Ka-li Kwok, Hong Kong
Prof. Albert Martin Man-chim Li, Hong Kong
Prof. Ching-yuang Lin, Taiwan
A/Prof. Sorasak Lochindarat, Thailand
Dr. Ting-yat Miu, Hong Kong
Prof. Ashkan Moslehi, Iran
Dr. Anna Nathan, Malaysia
Dr. Neptalie Ordonez, Philippines

General Information

The journal
Pediatric Respirology and Critical Care Medicine is a journal for pediatricians to discuss the latest clinical practice and research in pediatrics and child health. It is the official Journal of Asian Paediatric Pulmonology Society, Hong Kong Society of Paediatric Respirology and Allergy, and Taiwan Society of Pediatric Pulmonology and Critical Care Medicine. The journal’s full text is available online at http://www.preccm.org.

The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAIC-compliant institutional/subject-based repository.

Abstracting and indexing information
The journal is registered with the following abstracting partners: Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing’s Electronic Databases, Exlibris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, Netherlands ISSN center, ProQuest, TdNet.

Information for authors
The journal does not charge for submission, processing or publication of manuscripts and even for color reproduction of photographs. Please check http://www.preccm.org/contributors.asp for details. All manuscripts must be submitted online at http://www.journalonweb.com/preccm.

Advertising policies
The journal accepts display and classified advertising. Frequency discounts and special positions are available. Inquiries about advertising should be sent to Medknow Publications, advertise@medknow.com. The journal reserves the right to reject any advertisement considered unsuitable according to the set policies of the journal.

Copyright
The journal, however, grants to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and distribute derivative works in any digital medium for any reasonable non-commercial purpose, subject to proper attribution of authorship and ownership of the rights. The journal also grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.

Permissions
For information on how to request permissions to reproduce articles/information from this journal, please visit www.preccm.org.

Disclaimer
The information and opinions presented in this Journal reflect the views of the authors and not of the Journal or its Editorial Board or the Society of the Publisher. Publication does not constitute endorsement by the journal. Neither the Pediatric Respirology and Critical Care Medicine nor its publishers nor any other involved in creating, producing or delivering the Pediatric Respirology and Critical Care Medicine or the materials contained therein, assumes any liability or responsibility for the accuracy, completeness, or usefulness of any information provided in the Pediatric Respirology and Critical Care Medicine, nor shall they be liable for any direct, indirect, incidental, special, consequential or punitive damages arising out of the use of the Pediatric Respirology and Critical Care Medicine. The Pediatric Respirology and Critical Care Medicine nor its publishers, nor any other party involved in the preparation of material contained in the Pediatric Respirology and Critical Care Medicine represents or warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such material. Readers are encouraged to confirm the information contained herein with other sources.

Addresses

Editorial Correspondence
Prof. Gary Wing-kin Wong
Hong Kong Society of Paediatric Respirology and Allergy
4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wan Chai, Hong Kong
E-mail: wingkinwong@cuhk.edu.hk
Website: www.preccm.org

Published by
Wolters Kluwer India Private Limited
A-202, 2nd Floor, The Quebe, C.T.S. No.1498/A
Village Marol, Andheri (East), Mumbai - 400 059, India.
Phone: 91-22-66491818
Website: www.medknow.com
# Contents

## EDITORIAL

**The Challenges for Paediatric Respirologists**

Daniel Kwok-Keung Ng

71

## REVIEW ARTICLE

**Babies Who Don’t Get Better: When It’s Not Respiratory Distress Syndrome**

Steven M. Donn

72

## ORIGINAL ARTICLES

**Comparison of Ventilator-associated Pneumonia in Children Using Disposable and Nondisposable Ventilator Circuits**

Panida Srisan, Kallayanee Meechaijaroening

77

**Airway Disease and Environmental Aeroallergens in Eczematics Approaching Adulthood**

Ellis Kam Lun Hon, Meiruo Liu, Benny Zee

81
The Challenges for Paediatric Respirologists

One of the challenges facing paediatric respirologists is the wide range of diseases from neonates to adolescents that come to us frequently. You will no doubt find support from the current issue.

Respiratory distress is very common in neonates, pre-terms or otherwise, and it is not surprising that respirologists are often called upon by our neonatologists. You will find a very helpful article by Dr. Steve Donn on the approach to neonatal respiratory distress other than respiratory distress syndrome.\(^\text{[1]}\)

For the treatment of respiratory distress, ventilators are often involved. Srisan and Meechaijaroenying\(^\text{[2]}\) reported on the comparison of ventilator-associated pneumonia in children using disposable and non-disposable ventilator circuits, and it appeared that disposable circuits might not be cost-effective.

For the older age group, asthma is the bread and butter for paediatric respirologists and eczema is very often associated with asthma. Hon \textit{et al.}\(^\text{[3]}\) reported a long-term follow-up detailing the association between asthma and eczema.

As 2018 approaches, I would like to wish all readers a very successful 2018.

Daniel Kwok-Keung Ng
Department of Paediatrics, Kwong Wah Hospital, Hong Kong SAR, China

Address for correspondence: Dr. Daniel Kwok-Keung Ng, Department of Paediatrics, Kwong Wah Hospital, Hong Kong SAR, China. E-mail: dkkng@ha.org.hk

REFERENCES

Babies Who Don’t Get Better: When It’s Not Respiratory Distress Syndrome

Steven M. Donn
Department of Pediatrics and Communicable Diseases, Division of Neonatal-Perinatal Medicine, C.S. Mott Children’s Hospital, Michigan Medicine, Ann Arbor, Michigan, USA

Abstract

Most preterm and late preterm infants who require mechanical ventilation for respiratory failure resolve their disease process and can be extubated. A small percentage, however, continues to exhibit respiratory failure and remain ventilator dependent. There are myriad conditions that the clinician needs to consider, some of which are treatable, but some of which are lethal. Strategies for diagnosis and management are discussed herein.

Keywords: Mechanical intubation, newborn, respiratory failure

INTRODUCTION

Respiratory failure is the most common problem facing the prematurely born infant. Morphological and anatomical lung abnormalities interfere with adequate pulmonary gas exchange and may lead to the need for mechanical intubation. It is widely recognized that the indications for intubation and mechanical ventilation include inadequate oxygenation and/or ventilation, apnea, airway obstruction, and the need for control of the airway. The goals of mechanical ventilation include assisting the baby to achieve adequate gas exchange, optimizing patient-ventilator interactions, minimizing lung injury, and enhancing patient comfort while decreasing the patient work of breathing.

A recent survey of European neonatal intensive care units by Van Kaam et al.[1] queried the reasons for mechanical ventilation in newborns [Table 1]. Although nearly half had respiratory distress syndrome, the remainder exhibited varying conditions including sepsis, congenital malformations, apnea, asphyxia, pneumonia, and others.

Fortunately, most babies improve and are able to be weaned from support. In the past decades, we have improved our understanding of the pathophysiology of these disorders. We have been provided with an expanding array of better technology and an expanded drug formulary. This population possesses the potential for growth, generation of new tissue, and the ability to heal, and it exhibits great plasticity. Yet, some babies get stuck. They may fail to wean, fail to grow, or fail to respond to treatment.

PHYSIOLOGIC ESSENTIALS FOR EXTUBATION

A number of conditions must be achieved before a baby can be successfully extubated. First, there must be reliable respiratory spontaneous expiratory drive, the baby must display neuromuscular competence (the ability to transmit impulses from the respiratory center to the phrenic nerve and diaphragm), and there must be evidence of a reduced respiratory system load, characterized by the maintenance of oxygenation without intrinsic end-expiratory pressure, and adequate minute ventilation (tidal volume X frequency >240 mL/kg/min).[2] Numerous impediments to weaning and successful extubation have been recognized [Table 2]. Each of these factors alone can increase the work of breathing and complicate the process. Some, such as anemia and electrolyte imbalances, are easily

Address for correspondence: Prof. Steven M. Donn, 8-621 C.S. Mott Children’s Hospital, 1540 E. Hospital Drive, Ann Arbor, Michigan 48109-4254, USA. E-mail: smdonnmd@med.umich.edu

How to cite this article: Donn SM. Babies who don’t get better: When it’s not respiratory distress syndrome. Pediatr Respir Crit Care Med 2017;1:72-6.
correctable, while others are more problematic. When these conditions have been adequately addressed, and the infant is still dependent on mechanical ventilation, the clinician must consider the possibility of an unusual underlying pathologic entity.[3]

**Chronic Ventilator Dependence**

From a diagnostic standpoint, it may be easiest to classify the underlying problem into one of four categories: primary pulmonary disease (affecting the airway, lung parenchyma, or both); neurologic disease (central or peripheral); myopathy; and metabolic disease.

Table 3 lists malformations of the tracheobronchial tree. These conditions can be diagnosed by imaging (plain or contrast radiography, computed tomography, or magnetic resonance imaging) or airway endoscopy. Most – but not all – are amenable to surgical intervention. The advent of detailed fetal imaging has led to the prenatal diagnosis in many instances, and delivery room intervention (i.e., tracheostomy and EXIT procedure) can be planned in advance.

Malformations of the distal lung parenchyma are shown in Table 4. These represent a spectrum from easily treatable to lethal, so it is incumbent on the clinician to make an expedient diagnosis to institute appropriate therapy or to limit patient pain and discomfort through redirection of care. I will consider a few of these disorders with disparate prognoses to illustrate this point.[4-6]

**Alveolar capillary dysplasia**

This morphologic disorder was first described by Janney et al. in 1981.[7] There have been about 150 cases described in the medical literature, although the disease is probably much more prevalent. The exact etiology is unknown, but there are five reports of its occurrence in discordant siblings. Thus far, no karyotypic or cytogenetic abnormalities have been found.

It is believed to represent abnormal lung development during the pseudoglandular phase (4–16 weeks) and is characterized by arrested lung growth and development. The pulmonary veins adjacent to the pulmonary artery branches are displaced, and the arteries are also abnormal. The vessels share the arteriolar adventitia. The interlobular septa are abnormally broad with decreased numbers of capillaries, which fail to make contact with the alveolar epithelium. Thus, the blood-gas barrier is not formed normally, there is reduced pulmonary surface area, inadequate gas exchange, and pulmonary hypertension.

The usual clinical presentation is severe and intractable persistent pulmonary hypertension with unrelenting hypoxemia. Alveolar capillary dysplasia (ACD) occurs in term infants 90% of the time, often after normal Apgar scores. Half of the affected newborns present in the first 24 h. A later onset form has been reported, with signs appearing as late as 4–6 weeks. Pneumothorax is seen in half of the cases. Associated anomalies [Table 5] occur on 50%–65% of infants.

The chest radiograph in ACD may be initially unremarkable, or it may show mild haziness. Before 2000, more than 90% of cases were diagnosed by postmortem examination. Definitive diagnosis can be made by open lung biopsy.

ACD is a lethal disorder, with death occurring in the 1st day to weeks of age. There has been one reported survivor after lung transplant at 5 months of age.[8]

**Surfactant protein deficiency diseases**

Pulmonary surfactant is a complex mixture of phospholipids (90%) and proteins (10%). The first attempts at synthetic surfactant repletion in the 1960s, which failed, emphasized the importance of the surfactant-associated proteins.[9]
allow both hydrophobic and hydrophilic interactions, of alpha-helices containing multiple amphipathic domains, SP-B deficiency occurs in about 1 per million live births. Multiple different gene mutations, including nonsense, missense, frameshift, and splice site mutations have been identified. Infants with SP-B deficiency develop unresponsive respiratory failure, often resulting in unsuccessful extracorporeal membrane oxygenation therapy, and palliative care. The condition may show a temporary response to animal-derived surfactant administration but is uniformly lethal.\[11\]

\section*{SP-C deficiency}
SP-C deficiency occurs when the fluidity of the surfactant phospholipid bilayer accounting for its role in reducing alveolar surface tension. Its deficiency has a high phenotypic variance. Missense, frameshift, insertion, deletion, and splice site mutations have all been identified. In fact, there have been more than 35 dominantly expressed mutations, of which 55% are spontaneous. SP-C deficiency may be diagnosed at any age from early infancy to adulthood. The clinical spectrum ranges from asymptomatic to chronic respiratory insufficiency, and significant disease progressing to death or the need for lung transplantation.\[11\] It has been postulated that the possible mechanism of disease is the misfolding of proproteins that inhibit protein trafficking and result in cellular stress, injury, and apoptosis. Histopathologic changes include alveolar proteinosis, interstitial pneumonitis, and disorganized lamellar bodies. The diagnosis of either SP-B or SP-C deficiency can be made from a biochemical analysis of fluid obtained by tracheal aspiration. Genetic (DNA) sequencing can also be done (including ABCA3 mutations). Ultrastructural examination of lung biopsy specimens by electron microscopy can also be useful.

\section*{ABCA3 mutations}
The exact frequency of ABCA3 mutations is unknown, but it may be the most common disorder of surfactant homeostasis. More than 70 recessive mutations have been identified in lethal RDS in newborns and chronic respiratory insufficiency in children. The precise role of ABCA3 in surfactant metabolism remains elusive. Surfactant isolated from bronchoalveolar lavage fluid from ABCA3-deficient infants has significantly decreased phosphatidylcholine and markedly reduced function, suggesting that the ABCA3 mutation mediates phosphatidylcholine transport into lamellar bodies (which appear small and dense on electron microscopy). The absence of ABCA3 may also affect the trafficking of SP-B and SP-C.\[12\]

Different classes of mutations that result in the absence, misrouting, or altered function of the ABCA3 protein likely lead to differences in the clinical expression of disease.

\section*{INTERSTITIAL LUNG DISEASES}
Interstitial lung diseases (ILDs) refer to a group of pulmonary disorders involving both the airspaces and compartments of the
lung. They are relatively rare, but they can be associated with significant morbidity as well as mortality. A comprehensive review by Nogee was recently published and is highly recommended.[13]

**Pulmonary Interstitial Glycogenosis**

One of these entities is pulmonary interstitial glycogenosis (PIG), and because it is a non-lethal disorder, distinction of PIG from other lethal disorders is critical. The PIG was first described by Canakis et al. in 2002.[14] It is an atypical, noninfectious respiratory disorder, which may represent a possible developmental disorder of the lung. It should be distinguished from other forms of ILD, especially unusual interstitial pneumonitis, desquamative interstitial pneumonitis, and lymphoid interstitial pneumonitis.

On light microscopy, the lung tissue shows diffuse interstitial thickening, and the interalveolar septae are uniformly expanded by spindle type cells. Electron microscopy shows abnormalities of the interstitial cells, which have features of primitive mesenchymal cells, and they contain low contrast granular material suggestive of glycogen.

The clinical course of PIG is usually respiratory distress on the 1st day of life. Mechanical ventilation is generally required. The chest radiograph demonstrates large lung volumes, a coarse interstitial pattern, nonspecific haziness, and pneumothorax is common. The diagnosis can be confirmed by chest computed tomography or open lung biopsy.

In general, favorable outcomes have been reported for PIG. In the original series of Canakis et al., six of seven survived, and three had clinical resolution by the age of 6 years.[14] Thus, it is clear that this disorder must be distinguished from ACD and SP-B deficiency.

**Neuromuscular Disorders**

While it is beyond the scope of this review to present an in-depth discussion of all neuromuscular diseases that result in chronic respiratory insufficiency, several of the more common entities will be addressed. What these disorders have in common is a weakness of the respiratory muscles and the inability to compensate for increased respiratory loads. Airway clearance and recurrent pneumonia are also seen frequently. Ventilatory management of affected infants was recently reviewed by Alexiou and Piccione.[15]

**Neonatal Onset Spinal Muscular Atrophy (Type 1, Werdnig–Hoffman Disease)**

This lethal disorder is inherited as an autosomal recessive disease. It occurs in approximately 1/6000–1/10,000 live births and results from the absence of the SMN1 gene. Progressive destruction of the anterior horn cell leads to increasing weakness and loss of muscular function.[16]

**Spinal Muscular Atrophy with Respiratory Distress, Type 1**

This is another fatal infantile motor neuron disease. It causes diaphragmatic palsy, distal muscular weakness, muscle atrophy, sensory neuropathy, and autonomic nerve dysfunction. The IGHMBP2 gene has been implicated.[17]

**Congenital Myopathies**

This group of disorders includes diseases which primarily affect skeletal muscle fibers and are present at birth. An example is myotubular myopathy, an X-linked infantile myopathy. Muscle weakness and hypotonia, with resultant respiratory insufficiency, are the prominent findings. Affected fetuses may have reduced fetal movement, polyhydramnios (from a lack of swallowing), and thin ribs. After birth, there is severe hypotonia, muscle wasting, and generalized weakness. The majority of affected infants die in the 1st month of life. The diagnosis may be suspected by elevated muscle enzymes or abnormalities on electromyography, but only a muscle biopsy is confirmatory.[18]

**Congenital muscular dystrophies**

These are progressive disorders that lead to degeneration of muscle fibers. Congenital muscular dystrophy occurs in 0.68–2.5/100,000 live births. They are inherited as autosomal recessive diseases, although an autosomal dominant pattern has been reported. The specific type of muscular dystrophy can be determined by advanced diagnostic testing, including biochemical, genetic, and electromyographic.[18]

**Congenital myasthenic syndrome**

This is an inherited neuromuscular disorder caused by defects of the neuromuscular junction (either presynaptic, synaptic, or postsynaptic) and occurs once in half a million live births. It should be distinguished from the syndrome which affects infants born to mothers with myasthenia gravis, which is transient and improves with supportive care.[19]

**Prader–Willi syndrome**

This syndrome, characterized by hypotonia (and hence respiratory insufficiency), hypogonadism, hypom mentia, and obesity, is seen in 1/25,000–1/10,000 live births. It results from a deletion in the paternal chromosome 15 (q 11–13). Infants are often depressed or lethargic at birth and exhibit feeding difficulties as well as respiratory problems.[20]

**Evaluation of Intractable Respiratory Failure in the Newborn**

The evaluation of a newborn with intractable respiratory failure should begin with low-invasive, high-yield studies and only progress to the more invasive studies as the differential diagnosis is honed [Table 6]. Imaging, especially chest radiography, is usually the first step. If indicated, chest computed tomography or magnetic resonance imaging
may yield important information or rule out some entities. Flexible bronchoscopy is used to evaluate the upper airway and trachea, and is relatively safe when performed by skilled and experienced operators. Evaluation of lung fluid obtained by bronchoalveolar lavage is becoming a more widely utilized diagnostic test. Genetic studies should be obtained after consultation with a geneticist, who can help decide the appropriate analysis and adjuvant studies.

In cases where surgical biopsy is indicated, whether open lung or muscle, the diagnostic accuracy depends on the appropriate processing of the biopsy specimen. Care should be taken to orchestrate the entire procedure, among the various teams-surgery, laboratory, pathology, and ancillary services.

Finally, for patients who die without a definitive diagnosis, efforts should be taken to obtain a postmortem examination. While families are sometimes reluctant to give consent, a discussion which emphasizes the importance of finding an answer, as well as influencing subsequent family planning can do much to persuade parents to move forward.[21]

**Redirection of Care**

The decision to withdraw or withhold life support is a difficult one, subject to both individual beliefs and institutional practices and legal imperatives. It would seem reasonable that once the diagnosis of a lethal disorder has been made, efforts should focus on alleviation of pain and avoidance of suffering. In the case of a baby who is failing to respond, but does not have a specific diagnosis, it is less clear. A reasonable attempt to obtain a diagnosis and a reasonable attempt at therapeutic measures seems appropriate. It is up to the clinician and the family to determine what constitutes “reasonable.”

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

Financial support and sponsorship

family to determine what constitutes “reasonable.”

In the case of a baby who is failing to respond, but does not

should focus on alleviation of pain and avoidance of suffering.

RedIRectIon of caRe
do much to persuade parents to move forward.[21]

answer, as well as influencing subsequent family planning can

While families are sometimes reluctant to give consent, a

Finally, for patients who die without a definitive diagnosis,

various teams—surgery, laboratory, pathology, and ancillary

be taken to orchestrate the entire procedure, among the

appropriate processing of the biopsy specimen. Care should

lung or muscle, the diagnostic accuracy depends on the

by bronchoalveolar lavage is becoming a more widely

and experienced operators. Evaluation of lung fluid obtained

Flexible bronchoscopy is used to evaluate the upper airway

may yield important information or rule out some entities.

CT: Computed tomography, MRI: Magnetic resonance imaging

Muscle biopsy

Open lung biopsy

Bronchoalveolar lavage

Bronchoscopy

Chest radiography

respiratory failure

Table 6: Diagnostic evaluation of neonatal intractable


5. Lioy J, Greubel E, Sobel S. Malformations, deformations, and disorders

4. Lioy J, Sobel SE, editors. Disorders of the Neonatal Airway:

16. Prior TW. Perspectives and diagnostic considerations in spinal muscular

14. Canakis AM, Cutz E, Manson D, O’Brodovich H. Pulmonary interstitial


12. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant


8. Swenson AW, Donn SM. Alveolar capillary dysplasia: A lethal

6. Attar MA, Sarkar S. Developmental lung anomalies. In: Donn SM,


of the neonatal airway. In: Donn SM, Sinha SK, editors. Manual of


There are no conflicts of interest.

Conflicts of interest

Sinha SK, editors. Manual of Neonatal Respiratory Care. 4th ed. New York:

20. Tan HL, Urquhart DS. Respiratory complications in children with

19. Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic

18. Schorling DC, Kirschner J, Bönnemann CG. Congenital muscular

16. Prior TW. Perspectives and diagnostic considerations in spinal muscular

14. Canakis AM, Cutz E, Manson D, O’Brodovich H. Pulmonary interstitial


12. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant


8. Swenson AW, Donn SM. Alveolar capillary dysplasia: A lethal

6. Attar MA, Sarkar S. Developmental lung anomalies. In: Donn SM,


of the neonatal airway. In: Donn SM, Sinha SK, editors. Manual of


There are no conflicts of interest.

Conflicts of interest

Sinha SK, editors. Manual of Neonatal Respiratory Care. 4th ed. New York:

20. Tan HL, Urquhart DS. Respiratory complications in children with

19. Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic

18. Schorling DC, Kirschner J, Bönnemann CG. Congenital muscular

16. Prior TW. Perspectives and diagnostic considerations in spinal muscular

14. Canakis AM, Cutz E, Manson D, O’Brodovich H. Pulmonary interstitial


12. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant


8. Swenson AW, Donn SM. Alveolar capillary dysplasia: A lethal

6. Attar MA, Sarkar S. Developmental lung anomalies. In: Donn SM,


of the neonatal airway. In: Donn SM, Sinha SK, editors. Manual of


There are no conflicts of interest.

Conflicts of interest

Sinha SK, editors. Manual of Neonatal Respiratory Care. 4th ed. New York:

20. Tan HL, Urquhart DS. Respiratory complications in children with

19. Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic

18. Schorling DC, Kirschner J, Bönnemann CG. Congenital muscular

16. Prior TW. Perspectives and diagnostic considerations in spinal muscular

14. Canakis AM, Cutz E, Manson D, O’Brodovich H. Pulmonary interstitial


12. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant


8. Swenson AW, Donn SM. Alveolar capillary dysplasia: A lethal

6. Attar MA, Sarkar S. Developmental lung anomalies. In: Donn SM,


of the neonatal airway. In: Donn SM, Sinha SK, editors. Manual of


There are no conflicts of interest.

Conflicts of interest

Sinha SK, editors. Manual of Neonatal Respiratory Care. 4th ed. New York:
PEPTAMEN® JUNIOR is a nutritionally balanced, peptide-based enteral formula for children aged 1-10 years, for the dietary management of gastrointestinal impairment. It is suitable as a tube or oral feed for children requiring nutritional support.

- 100% whey protein
- To facilitate gastric emptying
- Enzymatically hydrolyzed to promote tolerance and absorption
- Improved nitrogen absorption and utilization (compared to intact protein or free amino acid formulations)

Indications for

- Gl impairment
- Malabsorption
- Short bowel syndrome
- Pancreatitis
- Delayed gastric emptying
- Cystic fibrosis
- Growth failure
- Cerebral Palsy
- Critical illness

MCTs can be easily absorbed and quickly used as energy

References:

IMPORTANT NOTICE: The World Health Organization recommends exclusive breastfeeding for 6 months. Nestlé fully supports this and continued breastfeeding, along with the introduction of complementary foods as advised by your doctor or health authority.
Comparison of Ventilator-associated Pneumonia in Children Using Disposable and Nondisposable Ventilator Circuits

Panida Srisan¹, Kallayanee Meechaijaroenying²

¹Department of Pediatrics, Division of Pulmonology and Critical Care, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University,
²Department of Pediatrics, Paolo Memorial Hospital, Bangkok, Thailand

Abstract

Aims: The aim of the study was to compare the incidence of ventilator-associated pneumonia (VAP), mortality, and ventilator circuit-related cost associated with patients using disposable ventilator circuit to those associated with patients using nondisposable ventilator circuit.

Setting and Design: A prospective randomized controlled study in a 10-bed Pediatric Intensive Care Unit at Queen Sirikit National Institute of Child Health between November 2011 and October 2012. Subjects and Methods: Children aged 1 month to 18 years who were ventilated >48 h were enrolled. Patients were randomized to be ventilated with a disposable or nondisposable heated wire ventilator circuit.

Statistical Analysis Used: Statistical analysis was performed using SPSS version 17.0. The P < 0.05 was considered statistically significant.

Results: Ninety-eight patients were enrolled. Of these, 48 were administered the disposable ventilator circuit, whereas 50 were administered the nondisposable ventilator circuit. The VAP rate was 20.53/1000 ventilator days for the former (n = 7) compared to 30.77/1000 ventilator days (n = 12) for the latter (odds ratio: 1.85; 95% confidence interval: 0.66–5.19, P = 0.24). The mortality rates were 2.1% in the disposable and 12% in the nondisposable circuit groups (P = 0.06). The unit cost of the disposable circuit (US dollar [USD] 51.60) was higher than that of the nondisposable circuit (USD 37.90). However, the total cost for the nondisposable group was higher due to the required use of more units (63 circuits for the disposable group vs. 95 circuits for the nondisposable group).

Conclusions: The type of ventilator circuit is not likely to affect the VAP rate and mortality in children. The unit cost of a disposable circuit is higher than that of a nondisposable circuit. The total cost depends on the number of circuits used in each patient.

Keywords: Disposable ventilator circuit, nondisposable ventilator circuit, ventilator day, ventilator-associated pneumonia

Introduction

Ventilator-associated pneumonia (VAP), the most important hospital-associated infection (HAI) in the Intensive Care Unit (ICU), is defined as pneumonia that occurs in a patient who is mechanically ventilated for at least 48 h.[1-5] It is associated with increased mortality, morbidity, length of stay, and health-related costs. The presence of an endotracheal tube (ETT) is the most important risk factor of VAP. Additional risk factors in children are underlying respiratory disease, longer duration of mechanical ventilation, genetic syndromes, immunodeficiency, continuous enteral feeding, the use of H₂ antagonist, the use of narcotics or neuromuscular blocking agents, previous antibiotic exposure, gastroesophageal reflux, younger age, reintubation, and supine positions.[2-4]

The prevention of VAP is essential in all ventilated patients.[1-13] Several strategies with the aim of preventing microaspiration, the colonization of the respiratory or the gastrointestinal tract by pathogenic organisms, or the contamination of ventilator equipment have been proven to be effective in adults and children. The possibility of cross infections from improperly cleaned nondisposable ventilator circuits and humidifiers was previously documented.[10,12,14,15] The use of disposable ventilator-related equipment is a standard practice in many developed countries because it involves a lower chance of infection and is more convenient to use. In contrast, the use of nondisposable ventilator circuits is more common in developing countries, including Thailand, due to their lower cost.
costs. There have been no previous studies comparing the incidence of VAP across different types of ventilator circuits. Therefore, this study was conducted to compare the incidence of VAP in children administered a disposable ventilator circuit to that in children administered a nondisposable ventilator circuit. The ventilator circuit-related costs and mortality of both groups were also compared.

**Subjects and Methods**

This research was a prospective randomized controlled study in the 10-bed-multidisciplinary pediatric ICU (PICU) of the Queen Sirikit National Institute of Child Health. The study was approved by the Institutional Review Board.

All the pediatric patients aged 1 month to 18 years who were intubated and mechanically ventilated for at least 48 h between November 2011 and October 2012 were enrolled. The exclusion criteria were ventilation for >48 h before admission to the PICU, postelective surgery, prior palliative care, and refusal of consent of a parent or a guardian.

The patients were randomly allocated to be ventilation with a disposable or a nondisposable ventilator circuit. The disposable circuit in this study was a dual heated wire breathing circuit (Evaqua™ 1, Fisher and Paykel Healthcare Ltd., Auckland, New Zealand). The nondisposable heated wire circuit came equipped with the ventilator having been sold to the hospital. The frequency of a ventilator circuit change was every 7 days for the former (Evaqua™ 1 user instruction) and every 5 days for the latter (our hospital policy). The disinfection process for the nondisposable circuit included wash with soap and clean water, chemical disinfection with sodium dichloroisocyanurate (Mediklean™), hot-air drying, and ethylene oxide gas sterilization, which was approximately 7 h.

The data collected included age, sex, weight, underlying disease, the pediatric risk of mortality (PRISM) III score, the risk factors of VAP, the duration of mechanical ventilation (number of ventilator days), the length of PICU stay, and mortality. VAP was diagnosed using the Centers for Disease Control and Prevention definition of nosocomial pneumonia.[10] That is, the incidence of VAP refers to the number of VAP cases per 1000 ventilator days. Ventilator utilization was expressed as a ratio of ventilator days to a PICU stay. The semi-quantitative culture of blood, sputum, or tracheal aspirate was used in this study.

The total ventilator circuit-related cost is the sum of material, labor, and maintenance costs. The labor cost is the total wage incurred on preparing, providing, and disinfection a ventilator circuit. The maintenance cost is calculated from the equipment and the depreciation cost of the disinfection process. All the costs were calculated in Thai Baht together with its equivalent in US dollars (USDs).

The sample size was calculated based on the VAP rate of 26.0/1000 ventilator days in nondisposable circuits (our previous VAP incidence) at the estimated VAP rate reduction of 30%. The result was 49 cases in each group.

All descriptive data were expressed as mean ± standard deviation or number (percentage). Categorical variables were analyzed using the Chi-square or the Fisher’s exact test. The unpaired t-test or the Mann–Whitney U-test was used to compare continuous variables. The P < 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS Statistical software version 17.0 (SPSS: International Business Machines Corp., New York, USA) (http://th. softonic.com/s/spss-17).

**Results**

Ninety-eight patients were enrolled. Of these, 50 (51%) were in the nondisposable circuit group, while 48 (49%) were in the disposable circuit group. The patient demographic data, the PRISM III scores, and the underlying diseases were not significantly different between the two groups. The most common underlying diseases in the disposable and the nondisposable circuit groups were cardiovascular diseases and genetic syndromes, respectively. The risk factors of VAP, including previous antibiotic exposure, retained nasogastric or orogastric tube, the use of H2 antagonist, sedation, open suction system, and reintubation, were not significantly different between the two groups [Table 1]. The most common cause of intubation was pneumonia with acute respiratory failure.

From the results, VAP occurred in 19 patients, 7 in the disposable circuit group and 12 in the nondisposable circuit group. The total VAP rate was 26.0/1000 ventilator days. The VAP rate was 14.6% and 20.53/1000 ventilator days in the disposable circuit group (12%) (OR: 0.16; 95% CI: 0.02–1.35, P = 0.24). There were no significant differences in ventilator days, PICU stay (days), ventilator circuit change interval for children from 3 to 7 days did not significantly differ between the two groups [Table 1]. The most common cause of intubation was pneumonia with acute respiratory failure.

The data collected included age, sex, weight, underlying disease, the pediatric risk of mortality (PRISM) III score, the risk factors of VAP, the duration of mechanical ventilation (number of ventilator days), the length of PICU stay, and mortality. VAP was diagnosed using the Centers for Disease Control and Prevention definition of nosocomial pneumonia.[10] That is, the incidence of VAP refers to the number of VAP cases per 1000 ventilator days. Ventilator utilization was expressed as a ratio of ventilator days to a PICU stay. The semi-quantitative culture of blood, sputum, or tracheal aspirate was used in this study.

The total ventilator circuit-related cost is the sum of material, labor, and maintenance costs. The labor cost is the total wage incurred on preparing, providing, and disinfection a ventilator circuit. The maintenance cost is calculated from the equipment and the depreciation cost of the disinfection process. All the costs were calculated in Thai Baht together with its equivalent in US dollars (USDs). The sample size was calculated based on the VAP rate of 26.0/1000 ventilator days in nondisposable circuits (our previous VAP incidence) at the estimated VAP rate reduction of 30%. The result was 49 cases in each group.

All descriptive data were expressed as mean ± standard deviation or number (percentage). Categorical variables were analyzed using the Chi-square or the Fisher’s exact test. The unpaired t-test or the Mann–Whitney U-test was used to compare continuous variables. The P < 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS Statistical software version 17.0 (SPSS: International Business Machines Corp., New York, USA) (http://th. softonic.com/s/spss-17).

**Table 1: Patient characteristics (n=98)**

<table>
<thead>
<tr>
<th>Patient data</th>
<th>Ventilator circuits</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (mean±SD)</td>
<td>2.23±3.80</td>
<td>3.16±3.87</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>29 (60.4)</td>
<td>26 (52.0)</td>
</tr>
<tr>
<td>Body weight (kg) (mean±SD)</td>
<td>9.95±9.73</td>
<td>13.22±10.25</td>
</tr>
<tr>
<td>PRISM III score (mean±SD)</td>
<td>2.79±2.8</td>
<td>3.38±3.62</td>
</tr>
<tr>
<td>Underlying diseases, n (%)</td>
<td>29 (60.4)</td>
<td>24 (48.0)</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>14 (29.2)</td>
<td>5 (10.0)</td>
</tr>
<tr>
<td>Genetic syndrome</td>
<td>5 (10.4)</td>
<td>6 (12.0)</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>3 (6.3)</td>
<td>1 (2.0)</td>
</tr>
<tr>
<td>Neurological</td>
<td>2 (4.2)</td>
<td>3 (6.0)</td>
</tr>
<tr>
<td>Others</td>
<td>5 (10.4)</td>
<td>9 (18.0)</td>
</tr>
<tr>
<td>H2 antagonist, n (%)</td>
<td>22 (45.8)</td>
<td>24 (48.0)</td>
</tr>
<tr>
<td>Previous antibiotic exposure, n (%)</td>
<td>47 (97.9)</td>
<td>49 (98.0)</td>
</tr>
<tr>
<td>NG or OGG tube, n (%)</td>
<td>42 (87.5)</td>
<td>41 (82.0)</td>
</tr>
<tr>
<td>Sedation, n (%)</td>
<td>40 (83.3)</td>
<td>44 (88.0)</td>
</tr>
<tr>
<td>Open suction system, n (%)</td>
<td>27 (56.3)</td>
<td>31 (62.0)</td>
</tr>
<tr>
<td>Reintubation, n (%)</td>
<td>2 (4.2)</td>
<td>1 (2.0)</td>
</tr>
</tbody>
</table>

NG: Nasogastric; OGG: Orogastric; SD: Standard deviation, PRISM: Pediatric risk of mortality.
days in the nondisposable circuit group (odds ratio [OR]: 1.85; 95% confidence interval [CI]: 0.66–5.19, \( P = 0.24 \)). There were no significant differences in ventilator days, PICU stays, and ventilator utilization between the two groups [Table 2]. The organisms isolated from the tracheal aspirates were Acinetobacter baumannii (50%), Pseudomonas aeruginosa (40%), and Klebsiella pneumoniae (10%).

Of all the cases, there were 7 deaths, 1 in the disposable circuit group (only in the non-V AP group) and 6 in the nondisposable circuit group (3 in the non-V AP group and 3 in the V AP group). The mortality rate in the disposable circuit group (2.1%) was not significantly different from that in the nondisposable circuit group (12%) (OR: 0.16; 95% CI: 0.02–1.35, \( P = 0.06 \)). Such deaths were caused mainly by severe sepsis (5/7), followed by pulmonary hemorrhage (1/7) and chronic lung disease (1/7). The OR for V AP death in the nondisposable circuit group was 3.9 [Table 2].

In terms of costs, the unit cost of a ventilator circuit was USD 51.60 for the disposable circuit compared to USD 37.90 for the nondisposable circuit. Nevertheless, due to its use of more circuits, the nondisposable circuit incurred a higher total cost of USD 3600 (95 circuits) compared to USD 3250 for the disposable circuit (63 circuits) [Table 3].

**Discussion**

V AP has been reported to occur in approximately 20% of all HAIIs in PICU, with the range of 1–63/1000 ventilator days.\(^2,3\) The incidence of V AP in this study (26.0/1000 ventilator days) was similar to that in our previous study in 2008 (26.0/1000 ventilator days) (unpublished data). In contrast, V AP rates in children have varied greatly depending on surveillance definitions, PICU settings, and national income levels.\(^1,3,10,16-18\) Several studies from Asia, including Thailand, reported V AP rates between 8 and 70/1000 ventilator days with the mortality between 5% and 23%.\(^1,18,19\) The pathogenesis of V AP involves the complex interactions between the presence of ETT, V AP risk factors, the virulence of bacteria, and host immunity. Pathogenic organisms can originate from either endogenous or exogenous sources. The aspiration of contaminated oropharyngeal secretions into the lower airway is a prerequisite for V AP development. The colonization of ETT, ventilator circuit, humidifier, nebulizer, or other respiratory equipment can also lead to lower airway contamination. V AP is rarely caused by hematogenous spread.\(^1,5,6,10-15\) The most common causative organisms are Gram-negative pathogens such as *P. aeruginosa*, *A. baumannii*, and *Enterobacteriaceae* with increasing reports of multidrug-resistant strains in Asia.\(^3,5,15,18,19\)

Recommendations for V AP prevention in children and adults include hand hygiene, head of bed elevation, oropharyngeal cleansing, sterilization or disinfection of respiratory equipment, no routine change of ventilator circuit, daily sedation interruption and assessment of readiness for weaning, active surveillance of V AP, and education of health-care staff.\(^1-14\) Multiple V AP preventive strategies are already implemented in our PICU, which may explain the comparable V AP rates between disposable and nondisposable circuits in this study.

From the findings, the main cost of a disposable circuit is material cost, whereas the costs of a nondisposable circuit predominantly involve both material and labor ones. In our hospital, the nondisposable circuit is usually used until it is broken (2–3 years). Despite its high cost, disposable circuits are increasing popular due to their elimination of cross infections and ease of use. However, a number of other factors need to be taken into consideration, especially labor availability, wage rates, and circuit change intervals. Labor shortage is currently an important issue worldwide, including in developing countries. A rise in wage rates will increase the labor and the unit costs of nondisposable circuits. Besides, if the circuit change interval can be extended, the number and costs of ventilator circuits will be decreased. Clinical practice guidelines recommend that ventilator circuits should not be changed routinely for infection control purposes. Although the maximum duration that circuits can be used safely is unknown, previous studies demonstrated that the extension of a ventilator circuit change interval for children from 3 to 7 days did not increase V AP rates and was cost-effective.\(^1,16,11,12,18\) The reason for the difference in the number of circuits was the use of a high-frequency oscillator required for some patients in the nondisposable circuit group.
There was a trend toward mortality in the nondisposable group (12%), compared to the disposable group (2.1%) \((P = 0.06)\). In the nondisposable circuit group, VAP death was 25% (3/12) and non-VAP death was 7.9% (3/38), with the OR of 3.9. If the number of patients was increased, the significant difference in mortality between disposable and nondisposable circuit groups might be demonstrated, included the difference between VAP and non-VAP death in the disposable circuit group.

VAP-related cost was not considered in this study as there was no difference in VAP rates between both groups. Nevertheless, VAP caused by multidrug-resistant bacteria is an emerging global problem, resulting in higher mortality and healthcare-related costs.\(^{[3,20]}\)

**Conclusions**

Our study suggests that the VAP rates between children using disposable and nondisposable ventilator circuits are not different. In addition, the ventilator circuit-related costs of disposable circuits are likely to be high.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

Airway Disease and Environmental Aeroallergens in Eczematics Approaching Adulthood

Ellis Kam Lun Hon¹, Meiruo Liu², Benny Zee²
¹Department of Paediatrics, The Chinese University of Hong Kong, ²Division of Biostatistics, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China

Abstract

Background: Atopic eczema (AE) is one of the most common skin diseases affecting children and adults worldwide. The “Atopic March” paradigm suggests AE is part of a complex condition with related airway disease. Objective: This study aimed to evaluate the prevalence of airway disease, environmental aeroallergens, and review factors associated with eczema severity and quality of life (QoL) when AE patients approached adulthood. Methods: Patients who were diagnosed with AE at a young age were included in the study and followed up till their adolescence at pediatric dermatology clinics from 2000 to 2017. Demographic characteristics, clinical laboratory parameters, treatment history, personal atopic history, as well as disease outcomes assessed by Nottingham Eczema Severity Score (NESS) and Children Dermatology Quality Life Index (CDLQI) were reviewed. Results: Three hundred and eighty-three patients (55.4% males) with latest NESS at mean (standard deviation) age 16.23 (2.50) years were reviewed. Personal history of asthma (45%), allergic rhinitis (74%), and family history of atopy were prevalent. Seventy-two percent of the patients were skin prick testing positive for house dust mite, 27% for cockroach, 33% for cat fur, and 13% for dog fur. Fourteen percent reported “smokers in family”. Multiple logistic regression showed “food avoidance ever” (adjusted odds ratio [OR] =3.00, 95% confidence interval [CI] =1.08–8.32; P = 0.035) and log-transformed immunoglobulin E (IgE) (adjusted OR = 1.45, 95% CI = 1.09–1.92; P = 0.011) were significantly associated with more severe AE. Linear regression showed “food avoidance ever” (β = 1.79, 95% CI = 0.34–3.24; P = 0.016), higher log-transformed IgE (β = 0.62; 95% CI = 0.22–1.03; P = 0.003), dog dander sensitization (β = 2.07, 95% CI = 0.24–3.89; P = 0.027), and severe disease (β = 2.97, 95% CI = 2.26–3.68; P < 0.001) were significantly associated with QoL impairment. Conclusions: A number of patients do not grow out of their eczema, and many of them have allergic rhinitis and asthma co-morbidities. Toward adulthood, AE severity and QoL are associated with food avoidance and high IgE, but generally independent of family or personal history of airway disease and allergen sensitization. Blood IgE measurement may help assess the risk for more severe eczema when patients are becoming adults.

Keywords: Adult, asthma, allergic rhinitis, aeroallergen, atopic eczema, Children Dermatology Life Quality Index, Nottingham Eczema Severity Score, prognosis

INTRODUCTION

Atopic eczema (AE) or atopic dermatitis is a chronically relapsing skin disorder affecting children and adults worldwide, with clinical symptoms of rash, inflammation, dry skin, and itch.¹⁻³ It is one of the most common skin diseases with global prevalence of 7.9% according to a cross-sectional questionnaire survey (International Study of Asthma and Allergies in Childhood Phase Three [1999–2004]), which showed an increasing trend comparing to the global prevalence of 6.1% reported in Phase One (1992–1997).⁴ In Hong Kong, AE prevalence among children aged 6–7 years old increased from 3.9% to 4.6%, and among children aged 13–14 years old from 2.7% to 3.3%.

With the increasing prevalence of AE, there are grave individual and social sequelae in terms of quality of life (QoL), financial, academic, and occupational burdens.⁵⁻⁷ For children with AE, not only physical symptoms such as itching, scratching, and sleep disorder impact their daily life but also psychological pressure such as social isolation, low self-esteem, and low self-confidence.⁸⁻⁹ The impacts of eczema including economic

Address for correspondence: Prof. Ellis Kam Lun Hon, Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, China. E-mail: ehon@hotmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Lun Hon EK, Liu M, Zee B. Airway disease and environmental aeroallergens in eczematics approaching adulthood. Pediatr Respirol Crit Care Med 2017;1:81-5.
burdens and QoL impairment are not only confined to the patients but also to their families. In most cases, families, especially parents with young AE patients would spend substantial financial costs, time, and effort in caring for them.

The etiology of eczema is complex, involving both genetic and environmental factors. Genetic mutation and environmental stimuli impair skin barrier, which ultimately manifests as eczema. Researches focusing on eczema etiology attract great attention because the elucidation of eczema pathophysiology would potentially lead to novel therapeutic strategies. The *filaggrin* gene (*FLG*) encoding a structural epidermal protein, along with a set of other proteins comprising epidermal differentiation complex, plays an important role in the intactness of skin barrier.[10] Recent studies gave evidence that loss-of-function mutation in *FLG* gene is associated with eczema.[11,12]

Epidemiologic researches on eczema identified a number of environmental risk factors including climate, diet, lifestyle, microbial agents, aeroallergens, and stress.[13] Aeroallergens such as house dust mite (HDM), pet fur, pollen, and smoke have been studied.[13] Broad spectrum antibiotic abuse might alter gut microbiota and lead to eczema exacerbation. High fat, low fruit and fish intake might be associated with increasing risk of eczema, there is no consistent evidence on the protective effect of exclusive breastfeeding.

It is a popular notion adopted by some parents and clinicians that children will outgrow eczema when they reach adolescence, but some long-term follow-up studies do not concur with this point of view. In a cross-sectional and cohort study targeting long-term registry of childhood eczema in the United States, it is concluded that eczema is probably a lifelong disease which persists into the second decade of children’s life.[14] A Hong Kong study similarly shows that eczema may persist when children grow older.[15] However, the follow-ups for both studies are too limited to draw conclusion on the progression of eczema when patients are reaching adulthood. According to the “Atopic March” paradigm, AE is part of a complex condition with related allergic hypersensitization involving the airways.[16-18] This study aimed to evaluate the prevalence of airway disease, environmental aeroallergens, and factors associated with eczema severity and QoL when AE patients approach adulthood.

**Methods**

Demographic characteristics of AE patients who were followed at the pediatric dermatology clinics of a teaching hospital between 2000 and 2017 to at least 16 years of age were reviewed. Patients diagnosed with AE were included in the study. Clinical information was recorded by the physicians on their first visit by means of clinician history taking, questionnaires, and laboratory tests which included disease severity, QoL, family and personal history of atopy, household pets, smoking, and therapeutic data. Clinical laboratory parameters included blood immunoglobulin E (IgE) (highest if multiple measurements), eosinophil counts, and skin prick testing if available.

Eczema onset age, prematurity, family atopy history, pets keeping, food avoidance, history of treatment (traditional Chinese medicine [TCM], immunomodulant, and wet wrap), feeding (breastfeeding or formula feeding) were recorded in clinicians’ consultations over the years.

Eczema severity is assessed by Nottingham Eczema Severity Score (NESS), which is a self-administered questionnaire with score ranging from 3 to 15, that divides patients into mild, moderate, and severe categories.[19,20] The validated Cantonese version of NESS questionnaire shows good agreement with SCORing Atopic Dermatitis (SCORAD).[21] The secondary outcome is assessed by Children Dermatology Life Quality Index (CDLQI), which is a questionnaire measuring the QoL of patients with skin disease.[22] Validation of the Cantonese version CDLQI shows that CDLQI scores correlated with physician-rated disease severity with good test-retest correlation ($P < 0.01$).[20,23]

Patients younger than 10 years of age or older than 22 years (if no prior NESS measurement) were excluded, and the characteristics of included and excluded patients were compared to assure that there is no substantial difference between them.

One-way ANOVA (Kruskal–Wallis one-way ANOVA for nonparametric data) was conducted to assess the association between categorical (more than three levels) and continuous variables. For binary and continuous variables, two sample t-test (Mann–Whitney test for nonparametric data) was performed. Chi-square test (Fisher’s Exact test for nonparametric data) was applied to investigate the association of categorical variables. Simple logistic regression was carried out to assess factors influencing odds of mild eczema versus moderate or severe disease. Multiple logistic regression was performed taking into account the association of categorical variables. Simple logistic regression was carried out to assess factors influencing odds of mild eczema versus moderate or severe disease. Multiple logistic regression was performed taking into account of sex, AE onset age, mother atopy status, breastfeeding ever, smoker in family ever, food avoidance ever, skin prick test (SPT), and highest IgE. Linear regression was performed to assess the effect of each factor with CDLQI. $P < 0.05$ was considered statistically significant. The University ethics committee approved this review.

**Results**

Totally 403 eczema patients were reviewed, 383 of whom with mean (standard deviation [SD]) age 16.23 (2.50) years were analyzed (Table 1).

When these patients approached adulthood, 123 patients had mild eczema, 137 patients with moderate eczema, and 123 patients with severe eczema. The percentage of male increased with more severe disease, which was 48.4% in mild group, 57.4% in moderate group, and 61.7% in severe group ($P = 0.037$). AE onset age was significantly associated with eczema severity, and patients with early disease...
onset (usually <1-year-old) generally had more severe AE in adolescence. The proportion of patients with treatment history including wet wrap, TCM, immunomodulant, and food avoidance increased with more severe eczema level ($P \leq 0.001$).

About 48.3% of eczema patients had asthma comorbidity, while the proportion did not differ between groups ($P = 0.637$); 78% of patients had allergic rhinitis, the difference of proportion between groups was not significant ($P = 0.175$).

64.6% of patients with mild eczema had reported they had food allergy, with 73.2% in moderate group, and 81.6% in severe group ($P = 0.013$).

Eosinophil percentage and highest IgE were both significantly associated with more severe eczema (Kruskal–Wallis test, $P < 0.001$).

SPT assessed sensitization to cat dander, dog dander, cockroach, house dust mite (HDM), and foods: 40.2% for cat, 16.0% for dog, and 33.7% for cockroach. Most patients were sensitized to HDM (88.4%). There was a significant association between HDM sensitization and eczema severity ($P < 0.001$). Sensitization to common foods occurred in 72.8% of patients, and the trend was not significantly associated with more severe disease ($P = 0.085$).

Multiple logistic regression was conducted to assess the adjusted odds ratio (OR) of mild eczema versus moderate or severe disease [Table 2]. Controlling for gender, AE onset age and mother atopy status, the adjusted OR for food avoidance ever was 3 (95% confidence interval [CI]: 1.08–8.32), and the adjusted OR for log-transformed IgE was 1.45 (95% CI: 1.09–1.92). None of the other clinical factors reached significance.

There were 247 patients with CDLQI data when they reached adolescence. Regression analysis showed that CDLQI increased by 1.79 point on average with food avoidance ever ($P = 0.016$) and by 0.62 per unit increase in log (IgE) ($P = 0.003$); CDLQI would increase or worsen by 2.07 points on average for patients with dog fur allergy ($P = 0.027$) [Table 3].

**DISCUSSION**

We followed up patients toward adulthood with the mean (SD) age 16.23 (2.50) years and recorded NESS scores as primary outcome. Our study was compatible with previous study that AE severity when patients were reaching adulthood may be associated with gender, young-onset age, treatment history, IgE and blood eosinophil counts, HDM, foods, cat fur, and dog fur sensitization. Importantly, the majority of AE patients in this cohort were troubled with moderate-to-severe disease. The secondary outcome, CDLQI, is associated with food avoidance, highest IgE, and skin sensitization for dog fur. Common to both outcomes, however, regression analysis showed that many of the clinical parameters were not predictive of AE severity or QoL when patients are approaching adulthood. The only relevant parameters were history of food avoidance and the IgE levels. A high blood IgE level may be predictive of a more severe disease course and quality of life impairment when the child grows up.

Another important observation is that many patients do report airway co-morbidities of asthma and allergic rhinitis, and food and aeroallergen sensitization. However, airway disease is

---

**Table 1: Demographics and clinical factors associated with atopic eczema severity toward adulthood**

<table>
<thead>
<tr>
<th></th>
<th>AE severity by NESS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild (n=123)</td>
<td>Moderate (n=137)</td>
</tr>
<tr>
<td>Mean±SD (years)</td>
<td>16.10±2.35</td>
<td>16.50±2.41</td>
</tr>
<tr>
<td>Male (%)</td>
<td>59 (48.4)</td>
<td>78 (57.4)</td>
</tr>
<tr>
<td>AE onset age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD (years)</td>
<td>3.01±3.37</td>
<td>3.26±4.08</td>
</tr>
<tr>
<td>Onset age &lt;1 year (%)</td>
<td>40 (41.2)</td>
<td>56 (45.2)</td>
</tr>
<tr>
<td>Treatment history (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wet wrap ever</td>
<td>21 (18.8)</td>
<td>48 (37.8)</td>
</tr>
<tr>
<td>TCM ever</td>
<td>44 (40.4)</td>
<td>78 (62.9)</td>
</tr>
<tr>
<td>Immunomodulant ever</td>
<td>5 (4.3)</td>
<td>18 (13.7)</td>
</tr>
<tr>
<td>Food avoidance ever</td>
<td>49 (48.0)</td>
<td>84 (68.3)</td>
</tr>
<tr>
<td>Personal atopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reported food allergy ever (%)</td>
<td>51 (64.6)</td>
<td>71 (73.2)</td>
</tr>
<tr>
<td>Eosinophils (Mean ± SD)</td>
<td>7.69±5.03</td>
<td>9.32±6.63</td>
</tr>
<tr>
<td>IgE (Mean ± SD) IU/L</td>
<td>2126.23±3897.68</td>
<td>5741.39±9200.92</td>
</tr>
</tbody>
</table>

**Skin prick test**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HDM sensitization (%)</td>
<td>73 (77.7)</td>
<td>106 (94.6)</td>
<td>98 (93.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Foods sensitization (%)</td>
<td>62 (66.7)</td>
<td>84 (73.7)</td>
<td>80 (77.7)</td>
<td>0.085**</td>
</tr>
<tr>
<td>CDLQI (mean ± SD)</td>
<td>4.45±3.96</td>
<td>6.89±4.11</td>
<td>10.35±5.03</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Fisher’s exact test, †Kruskal-Wallis test, **Trend test. SD: Standard deviation, CDLQI: Children Dermatology Life Quality Index, HDM: House dust mite, AE: Atopic eczema, NESS: Nottingham Eczema Severity Score, TCM: Traditional Chinese medicine
generally independent of AE severity and QoL. Nevertheless, another study reported significant relationship between AE severity, bronchial asthma, allergic rhinitis, and the duration of the skin lesions.\(^{[25]}\) Regardless, these associated atopic diseases are prevalent among AE patients.

For strength of the study, it is a long-term follow-up study, with focus on eczema severity toward adulthood. We recorded the clinical factors from early years and updated the clinical information from time to time. NESS was used as instrument to assess AE severity which is more appropriate in comparing long-term change of disease status than SCORAD which assesses AE severity within 1 week. CDLQI toward adulthood as the secondary outcome is another innovative point for our study.

For the weakness of the study, there are missing data for some factors, notably the laboratory tests. Also, many young children are not reaching adulthood after years of follow-ups and have to be excluded from this review. Some children may refuse laboratory tests, and hence only clinical parameters are available. Consequently, multiple regression is hard to perform due to considerable loss of power. Furthermore, genetic confounders or lifestyle and socioeconomic status confounders were not included. Inevitably, in the tertiary hospital setting, the population of subjects are likely to be biased toward more severe disease.\(^{[90]}\)

In terms of foods sensitization (as evidenced by SPT), the increasing trend with more severe eczema is consistent with other studies. Two-thirds of mild eczema patients are sensitive to foods by SPT.\(^{[27-31]}\) Considering that most children are not exposed to many foods before 3 years of age, interpreting the frequency of those who are sensitive to foods by SPT and reported foods allergen exposure after age 3 would be more meaningful. However, food sensitization does not equate with genuine food allergy. Food allergen sensitization as evidence by positive skin prick testing is not associated with more severe disease or worse quality of life in children with AE. Conversely, food avoidance, often indiscriminatively practiced, is associated with more severe disease and worse quality of life.

Many parents may report adverse food reactions in their children with AE. Although sensitization to food and aeroallergens are prevalent, it has been demonstrated that the prevalence of genuine food allergy is low and indiscriminate food avoidance does not alleviate symptoms of AE and airway allergies.\(^{[29,32-34]}\)

### Conclusions

A number of patients do not grow out of their eczema, and many of them have allergic rhinitis and/or asthma. AE may remain severe toward adulthood. AE severity and QoL are associated with food avoidance and high IgE, but generally independent of family or personal history of airway disease and allergen sensitization. As the age when the IgE was assessed was not standardized in this retrospective study, it is not sure if blood IgE measurement may truly help assess

---

**Table 2: Multiple logistic regression analysis of patient characteristics on atopic eczema severity**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Unadjusted OR (95% CI)</th>
<th>P</th>
<th>Adjusted OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>1.56 (1.01-2.41)</td>
<td>0.044</td>
<td>0.94 (0.37-2.39)</td>
<td>0.896</td>
</tr>
<tr>
<td>Male onset age &lt;1</td>
<td>1.51 (0.94-2.44)</td>
<td>0.090</td>
<td>0.88 (0.34-2.28)</td>
<td>0.791</td>
</tr>
<tr>
<td>Mother atopy</td>
<td>0.74 (0.47-1.17)</td>
<td>0.200</td>
<td>0.54 (0.21-1.39)</td>
<td>0.202</td>
</tr>
<tr>
<td>Breastfed ever</td>
<td>0.79 (0.44-1.41)</td>
<td>0.422</td>
<td>0.51 (0.20-1.29)</td>
<td>0.155</td>
</tr>
<tr>
<td>Smoker ever</td>
<td>1.24 (0.67-2.29)</td>
<td>0.489</td>
<td>3.03 (0.7911-6.60)</td>
<td>0.106</td>
</tr>
<tr>
<td>Food avoidance ever</td>
<td>2.80 (1.73-4.53)</td>
<td>&lt;0.001</td>
<td>3.00 (1.08-8.32)</td>
<td>0.035</td>
</tr>
<tr>
<td>Skin prick test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDM positive</td>
<td>4.51 (2.15-9.48)</td>
<td>&lt;0.001</td>
<td>3.01 (0.74-12.22)</td>
<td>0.123</td>
</tr>
<tr>
<td>Cat fur positive</td>
<td>1.48 (0.89-2.44)</td>
<td>0.129</td>
<td>0.38 (0.14-1.04)</td>
<td>0.059</td>
</tr>
<tr>
<td>Dog fur positive</td>
<td>1.91 (0.91-4.00)</td>
<td>0.087</td>
<td>3.66 (0.84-16.04)</td>
<td>0.085</td>
</tr>
<tr>
<td>Log transformed IgE</td>
<td>1.50 (1.27-1.77)</td>
<td>&lt;0.001</td>
<td>1.45 (1.09-1.92)</td>
<td>0.011</td>
</tr>
</tbody>
</table>

HDM: House dust mite, AE: Atopic eczema, CI: Confidence interval

**Table 3: Simple linear regression analysis of patient characteristics on Children Dermatology Life Quality Index**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>β (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>−0.41 (−1.68-0.85)</td>
<td>0.521</td>
</tr>
<tr>
<td>Premature</td>
<td>−1.51 (−5.96-2.94)</td>
<td>0.502</td>
</tr>
<tr>
<td>First born</td>
<td>−0.48 (−1.83-0.88)</td>
<td>0.490</td>
</tr>
<tr>
<td>AE onset age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AE onset age &lt;1</td>
<td>0.06 (−1.25-1.36)</td>
<td>0.934</td>
</tr>
<tr>
<td>Feeding patterns</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formula fed ever</td>
<td>6.06 (−3.51-15.63)</td>
<td>0.212</td>
</tr>
<tr>
<td>Breastfed</td>
<td>0.31 (−1.23+1.85)</td>
<td>0.698</td>
</tr>
<tr>
<td>Breastfed period (month)</td>
<td>−0.08 (−0.26-0.11)</td>
<td>0.423</td>
</tr>
<tr>
<td>Family atopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Father atopy</td>
<td>−0.83 (−2.10-0.44)</td>
<td>0.200</td>
</tr>
<tr>
<td>Mother atopy</td>
<td>−0.69 (−1.98-0.59)</td>
<td>0.290</td>
</tr>
<tr>
<td>Siblings atopy</td>
<td>−1.15 (−2.96-0.67)</td>
<td>0.215</td>
</tr>
<tr>
<td>Personal atopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal AR</td>
<td>−1.33 (−2.85-0.20)</td>
<td>0.088</td>
</tr>
<tr>
<td>Personal AS</td>
<td>−0.17 (−1.42-1.08)</td>
<td>0.795</td>
</tr>
<tr>
<td>Pet ever</td>
<td>−0.37 (−2.41-1.66)</td>
<td>0.718</td>
</tr>
<tr>
<td>Smoker ever</td>
<td>−0.24 (−1.91-1.42)</td>
<td>0.773</td>
</tr>
<tr>
<td>Food avoidance ever</td>
<td>1.79 (0.34-3.24)</td>
<td>0.016</td>
</tr>
<tr>
<td>Log-transformed IgE</td>
<td>0.62 (0.22-1.03)</td>
<td>0.003</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>0.07 (−0.02-0.17)</td>
<td>0.127</td>
</tr>
<tr>
<td>Food allergy ever</td>
<td>−0.44 (−2.21-1.33)</td>
<td>0.624</td>
</tr>
<tr>
<td>Skin prick test</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cat sensitization</td>
<td>0.98 (−0.37-2.33)</td>
<td>0.155</td>
</tr>
<tr>
<td>Dog sensitization</td>
<td>2.07 (0.24-3.89)</td>
<td>0.027</td>
</tr>
<tr>
<td>Cockroach sensitization</td>
<td>0.15 (−1.25-1.55)</td>
<td>0.833</td>
</tr>
<tr>
<td>HDM sensitization</td>
<td>0.17 (−2.06-2.39)</td>
<td>0.883</td>
</tr>
<tr>
<td>Food sensitization</td>
<td>−0.42 (−1.94-1.10)</td>
<td>0.586</td>
</tr>
<tr>
<td>NESS</td>
<td>2.97 (2.26-3.68)</td>
<td>−0.001</td>
</tr>
</tbody>
</table>

AR: Allergic rhinitis, AS: Asthma, NESS: Nottingham Eczema Severity Score, HDM: House dust mite, AE: Atopic eczema, CI: Confidence interval
the risk for more severe eczema when patients are becoming adults. Nevertheless, higher IgE can serve as a marker of more severe atopy.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**REFERENCES**

Pediatric Respirology and Critical Care Medicine now accepts articles electronically. It is easy, convenient and fast. Check following steps:

<table>
<thead>
<tr>
<th>1 Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Register from <a href="http://www.journalonweb.com/prcm">http://www.journalonweb.com/prcm</a> as a new author (Signup as author)</td>
</tr>
<tr>
<td>• Two-step self-explanatory process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2 New article submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prepare your files (Article file, First page file and Images, if any)</td>
</tr>
<tr>
<td>• Login into your area</td>
</tr>
<tr>
<td>• Click on 'Submit a new article' under 'New Article'</td>
</tr>
<tr>
<td>• Follow the steps (three steps for article without images and five for with images)</td>
</tr>
<tr>
<td>• On successful submission you will receive an acknowledgement quoting the manuscript numbers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3 Tracking the progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Click on 'In Review Article' under ‘Submitted Articles’</td>
</tr>
<tr>
<td>• The table gives status of the article and its due date to move to next phase</td>
</tr>
<tr>
<td>• More details can be obtained by clicking on the Manuscript ID</td>
</tr>
<tr>
<td>• Comments sent by the editor and referee will be available from these pages</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4 Submitting a revised article</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Click on 'Article for Revision' under ‘Submitted Articles’</td>
</tr>
<tr>
<td>• Click on 'Revise'</td>
</tr>
<tr>
<td>• From the first window, you can modify Article Title, Article Type</td>
</tr>
<tr>
<td>• First Page file and Images could be modified from second and third window, respectively</td>
</tr>
<tr>
<td>• The fourth step is uploading the revised article file.</td>
</tr>
<tr>
<td>• Include the referees' comments along with the point to point clarifications at the beginning of the revised article file.</td>
</tr>
<tr>
<td>• Do not include authors’ name in the article file.</td>
</tr>
<tr>
<td>• Upload the revised article file against New Article File - Browse, choose your file and then click “Upload” OR Click “Finish”</td>
</tr>
<tr>
<td>• On completion of revision process you will be able to check the latest file uploaded from Article Cycle (In Review Articles -&gt; Click on manuscript ID - &gt; Latest file will have a number with 'R')</td>
</tr>
</tbody>
</table>

### Facilities
- Submission of new articles with images
- Submission of revised articles
- Checking of proofs
- Track the progress of article in review process

### Advantages
- Any-time, any-where access
- Faster review
- Cost saving on postage
- No need for hard-copy submission (except on acceptance images should be sent)
- Ability to track the progress
- Ease of contacting the journal

### Requirements for usage
- Computer and internet connection
- Web-browser (preferably newer versions - IE 5.0 or NS 4.7 and above)
- Cookies and javascript to be enabled in web-browser

### Online submission checklist
- First Page File (text/rtf/doc/pdf file) with title page, covering letter, acknowledgement, etc.
- Article File (text/rtf/doc/pdf file) - text of the article, beginning from Title, Abstract till References (including tables). File size limit 1 MB. Do not include images in this file.
- Images (jpeg): Submit good quality colour images. Each image should be less than 4096 kb (4 MB) in size.

### Help
- Check Frequently Asked Questions (FAQs) on the site
- In case of any difficulty contact the editor
ALL PRESERVATIVE FREE
New formulations to optimise nasal epithelial function

**FLO® Sinus Care Starter Kit**
- Recommended for congestion from Acute Sinusitis, Chronic Sinusitis and Allergies
- Also ideal for Post Operative care
- Preservative and Medication FREE
- Isotonic - No Sting formula
- More gentle than concentrated salt solutions
- May be used during pregnancy

**FLO® Baby Saline+ Nasal Spray**
- Recommended for Infants’ blocked nose
- 15mL pack size
- Sterile and Preservative FREE
- Isotonic - No Sting formula
- Sprays at any angle
- Quick and easy to use
- Comfy for baby and parents

**FLO® Refill 50**
- Recommended for congestion from Acute Sinusitis, Chronic Sinusitis, Allergies and Post Operative care
- Refill pack - 50 sachets pack size for on-going and long term use
- Preservative and Medication FREE
- Isotonic - No Sting formula
- More gentle than concentrated salt solution

**FLO® Kids Saline+ Nasal Spray**
- Recommended for children from 5 years of age and older with blocked nose
- 15mL pack size
- Sterile and Preservative FREE
- Isotonic - No Sting formula
- Sprays at any angle
- Quick and easy to use
- Children who are involved in their own treatment are often happier and more operative, making them easier to treat

**Nozoil® Nasal Spray**
- Relief of dry, crusty or bleeding nose
- Moisturises, heals and protects nasal tissue
- Contains Sesamum Indicum 1mg/mL with natural Vitamin E
- Proven superior to saline spray
- Proven effective in clinical trials in CPAP therapy
- Odourless to improve compliance
- 15mL pack size

**FLO® Saline+Plus Nasal Spray**
- Recommended for Colds and Flu, Rhinitis, Sinusitis, Hay fever, Blocked nose caused by pregnancy.
- Post Operative use
- 30mL pack size
- Sterile and Preservative FREE
- Isotonic - No Sting formula
- Includes added minerals

YouTube: How to wash your sinuses with FLO Sinus Care
YouTube: How to clear baby’s blocked nose with FLO Baby

Further product information is available upon request from:
Sino-Asia Pharmaceutical Supplies Ltd.
Tel: (852) 2573 1400  Fax: (852) 2575 0826
Email: info@sinoasia.com.hk  website: http://www.sinoasia.com.hk
SAVE THE DATES

15 April 2018
21st TPPCCM Annual Meeting
Taichung, Taiwan (R.O.C.)

15 – 17 August 2018
Airway Endoscopy Course
Bangkok, Thailand

20 – 21 October 2018
21st HKSPRA Annual Scientific Meeting
Hong Kong SAR, China

7 – 9 December 2018
4th APPS Annual Scientific Congress
Beijing, China

15 – 16 December 2018
Paediatric Respiloogy Medicine Training Course
Ho Chi Minh City, Vietnam